These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 20363564)
21. Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan. Martinez-Balibrea E; Manzano JL; Martinez-Cardus A; Moran T; Cirauqui B; Catot S; Taron M; Abad A Oncol Rep; 2007 Mar; 17(3):637-45. PubMed ID: 17273745 [TBL] [Abstract][Full Text] [Related]
22. The prognostic importance of thymidylate gene polymorphism in colon cancer stage II. Dysager L; Jensen LH; Lindebjerg J; Jakobsen A Int J Colorectal Dis; 2008 Dec; 23(12):1267. PubMed ID: 18629514 [No Abstract] [Full Text] [Related]
23. The role of molecular markers in predicting response to therapy in patients with colorectal cancer. Shankaran V; Wisinski KB; Mulcahy MF; Benson AB Mol Diagn Ther; 2008; 12(2):87-98. PubMed ID: 18422373 [TBL] [Abstract][Full Text] [Related]
24. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil. Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586 [TBL] [Abstract][Full Text] [Related]
25. Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Spano JP; Milano G; Vignot S; Khayat D Crit Rev Oncol Hematol; 2008 Apr; 66(1):21-30. PubMed ID: 18206383 [TBL] [Abstract][Full Text] [Related]
26. Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer. Ramos FJ; Macarulla T; Capdevila J; Elez E; Tabernero J Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S52-7. PubMed ID: 19064407 [TBL] [Abstract][Full Text] [Related]
27. Role of genomic markers in colorectal cancer treatment. Allen WL; Johnston PG J Clin Oncol; 2005 Jul; 23(20):4545-52. PubMed ID: 16002846 [TBL] [Abstract][Full Text] [Related]
28. Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer. Al-Hajeili M; Shields AF; Hwang JJ; Wadlow RC; Marshall JL Oncology (Williston Park); 2017 Apr; 31(4):301-12. PubMed ID: 28412781 [TBL] [Abstract][Full Text] [Related]
29. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Vokes EE; Chu E Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979 [TBL] [Abstract][Full Text] [Related]
30. [Predictive factors of response to anti-EGFR treatments in colorectal cancer]. Lièvre A; Laurent-Puig P Bull Cancer; 2008 Jan; 95(1):133-40. PubMed ID: 18230579 [TBL] [Abstract][Full Text] [Related]
31. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. László L Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770 [TBL] [Abstract][Full Text] [Related]
32. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Etienne-Grimaldi MC; Formento JL; Francoual M; François E; Formento P; Renée N; Laurent-Puig P; Chazal M; Benchimol D; Delpero JR; Letoublon C; Pezet D; Seitz JF; Milano G Clin Cancer Res; 2008 Aug; 14(15):4830-5. PubMed ID: 18676755 [TBL] [Abstract][Full Text] [Related]